Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance
Abstract In the treatment of chronic myeloid leukemia (CML), resistance to BCR‐ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecu...
Guardat en:
| Autors principals: | , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Wiley
2024-08-01
|
| Col·lecció: | Pharmacology Research & Perspectives |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1002/prp2.1214 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|